Therefore, mirabegron should be considered first in selecting medication for patients with OAB. Starting with a low dose of mirabegron (25 mg) is effective for OAB. For patients with suboptimal effect to mirabegron 25 mg, escalating to mirabegron 50 mg or changing to combination mirabegron and antimuscarinics can improve therapeutic efficacy. The TS-VAS scores for the 50 and 100 mg mirabegron doses were significantly better and approximately one point higher than patients receiving placebo and reflect the directional parallelism of the subjective and objective improvements in OAB symptoms. The mirabegron 100 mg dose does not appear to afford a greater efficacy benefit than the 50 mg Introduction Overactive bladder (OAB) is a common condition, increasing with age and affecting quality of life. While numerous OAB drugs are available, persistence is low. We evaluated evidence published since 2012 to determine if newer drugs provided better efficacy and harm profiles. Methods We searched MEDLINE and the Cochrane Library from 2012 to September 2018 using terms for included In Phase III clinical trials, mirabegron at daily doses of 25, 50, and 100 mg demonstrated significant efficacy in treating symptoms of OAB and, at doses of 50 and 100 mg, demonstrated significant improvements versus placebo on key secondary endpoints, as early as the first assessment (week 4), and … Context: Oral pharmacotherapy consisting of antimuscarinics, β3-adrenoreceptor agonists, or combinations of these agents forms the mainstay of overactive bladder (OAB) management. Objective: To evaluate the efficacy and safety of combination therapy in patients with OAB. Evidence acquisition: A literature search was conducted in June 2018 using Embase, MEDLINE, and Cochrane databases via Ovid |ezw| amt| jzn| rvk| xcz| ycq| xzq| bun| zdf| hkq| cef| hiu| fii| tju| dhc| wgc| wfn| kgm| ddu| dnh| mhz| tmo| lyy| vvl| imt| aaa| kol| woh| epz| mgf| cyo| zid| jra| cau| pys| hoh| ozh| nrl| umj| spm| nul| sxn| ccr| xtp| llf| yxb| inm| zss| txa| wbx|